Navigation Links
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer
Date:1/13/2014

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and technical expertise to discover and manufacture novel first-in-class and best-in-class biologic clinical development candidates to advance into the Pharmaceutical and Biotechnology company pipelines.

Dr. Reff received his Ph.D. in Medical Microbiology from Stanford University School of Medicine, and his Bachelor's degree in Chemistry from Massachusetts Institute of Technology. This was followed by a  Postdoctoral Fellowship at Harvard Medical School, and  a position at the National Cancer Institute. Dr. Reff then spent 8 years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering. After that, he joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr. Reff had a distinguished 21 year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered 6 novel oncology drugs into clinical trials in 5 years.

In early 1990s, Dr. Reff was Project Leader targeting B cell lymphoma, building and expressing the chimeric mouse-human anti-CD20 monoclonal antibody (Rituxan), the first monoclonal antibody approved to treat a tumor. Dr. Reff led the efforts from discovery until Rituxan entered its pivotal clinical trial.

Dr. Reff is well-recognized in the pharmaceutical and research community having been listed as an inventor on approximately 29 patents and patent applications, and as an author in nearly 100 scientific publications and presentations.

About ShangPharma:

ShangPharma Corp is a leading contract research organization (CRO) providing a broad range of high-quality, integrated services across both drug discovery and drug development to help pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company today has a team of nearly 2,000 skilled scientists in 1 million square feet of state-of-the-art research facilities and office space. For more information, please visit: http://www.ShangPharma.com. ChemPartner is a wholly owned subsidiary of ShangPharma Corp and also the main brand of the group.


'/>"/>
SOURCE ShangPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Corporation Announces Completion of Merger
2. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
3. ShangPharma Announces Third Quarter 2012 Results
4. ShangPharma to Report Third Quarter 2012 Financial Results on November 20, 2012
5. ShangPharma and Harbour Antibodies Announce Licensing Agreement
6. ShangPharma Announces Second Quarter 2012 Results
7. ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012
8. ShangPharma Independent Committee Appoints Financial Advisor
9. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
10. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
11. ShangPharma Announces First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Ill. , Dec. 5, 2016 For ... score on the 2017 Human Rights Campaign Foundation,s ... The CEI is a national benchmarking tool used to ... bisexual, and transgender (LGBT) employee equality. For ... Survey to help companies gauge their equality efforts, culture ...
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
(Date:12/5/2016)... Dec. 5, 2016  Seno Medical Instruments, Inc., the ... new tool to improve the process of diagnosing breast ... its European MAESTRO post-market surveillance and clinical follow-up study ... (SABCS) taking place from December 6-10, 2016 at ... San Antonio, Texas . Seno Medical ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... An ... much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a unique ... most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day water ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... Keeping Gift ... people choose gifts that are safe and age-appropriate for their recipients. This is the ... to reflect on the safety of items that would make good gifts for children. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for Great Britain . Leading ... of their EHS regulatory obligations and rapidly collect, share, archive, and export audit ...
(Date:12/6/2016)... ... 06, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has announced the addition of a Public Sector ... training to public sector employees. , “The primary goal of the Public Sector ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
Breaking Medicine News(10 mins):